Most peptides are broken down by ordinary proteolysis and cleared through the kidneys, rather than metabolised by the cytochrome P450 (CYP450) liver enzyme system — the pathway responsible for the majority of classic small-molecule drug-drug interactions. This means peptides generally carry a lower interaction risk profile than typical pharmaceutical drugs.
That doesn't mean zero interaction risk. Growth-hormone-axis peptides (GHRH analogues, GHRPs) can measurably reduce insulin sensitivity, so anyone on insulin or oral antidiabetic medication should monitor fasting glucose and HbA1c more closely when starting a GH-secretagogue protocol. Peptides that promote tissue repair and angiogenesis, such as BPC-157, warrant extra awareness for anyone on blood-thinning medication, given their effects on vascular tissue. Thyroid-modulating peptides should not be combined with thyroid replacement therapy without medical guidance.
The practical rule: disclose every current medication to whoever is guiding your research protocol before starting, particularly anything affecting blood sugar, clotting, or hormone regulation — these are the categories where a real interaction is plausible.
Study-backed guides, dosing protocols, and the full research peptide collection — all in one place.